Clinical trials: PET-CT
Lung Cancer, Solitary Pulmonary Nodule
4-[18F]Fluoroglutamine PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules
This clinical trial studies positron emission tomography (PET) imaging utilizing 18F-(2S,4R)4-fluoroglutamine, a glutamic acid derivative, to image patients with Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules.
- Conditions
- Lung Cancer, Solitary Pulmonary Nodule, Cigarette Smoking Behavior
- Trial name
- GLN (NCT03568799)
- Testing
- 18F-(2S,4R)4-fluoroglutamine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Neoplasms
68Ga-N188 PET/CT Imaging in Malignancy
The Nectin-4 protein belongs to the cell adhesion factors family and has a tissue-specific expression spectrum in normal human tissues.
- Trial name
- NCT05593107
- Testing
- [68Ga]N188
- Where
- China
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Breast Cancer Invasive, Node Positive Breast Cancer
Exploring the Tumor Micro-Environment with 68Ga-FAPi-46 PET/CT in Breast Cancer
This study is a prospective, non-interventional, open-label study to evaluate the glucose metabolism and the expression of the imaging agent 68 Gallium-Fibroblast Activation Protein Inhibitor-46 (68Ga-FAPi-46) with PET imaging…
- Trial name
- FAPI-PET (NCT06790264)
- Testing
- 68Ga-FAPi-46 PET/CT
- Where
- Italy
- Volunteers
- 92 people
- Sponsor
- European Institute of Oncology
Cardiovascular Disease, Atherosclerosis
Cardiovascular Molecular Calcification Assessed by 18F-NaF PET CT
The purpose of the CAMONA study is to demonstrate the feasibility of cardiovascular molecular calcification (CMC) assessment by means of 18F-sodium-fluoride (18F-NaF) positron emission tomography (PET) computed tomography (CT) in…
- Conditions
- Cardiovascular Disease, Atherosclerosis, Angina Pectoris
- Trial name
- CAMONA (NCT01724749)
- Where
- 2 sites in Denmark
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
Prostate Cancer
High-resolution Intra-operative PSMA PET-CT in Prostate Cancer
This is a Single-center, diagnostic open-label prospective, pilot study in a total of 10 patients affected by Prostate cancer (PCa) with a risk of lymph node invasion (LNI) higher than 5% and candidates for a robot-assisted…
- Trial name
- NCT06298838
- Testing
- AURA10® Specimen PET/CT imager
- Volunteers
- 10 people
- Sponsor
- IRCCS San Raffaele
Cancer
18F-FAPI and 18F-FDG PET/CT in Patients With Various Types of Cancer
FAP is overexpressed in the cancer-associated fibroblasts (CAFs) of 90% epithelial carcinomas. Currently, 68Ga-fibroblast activation protein inhibitor (FAPI) has shown promising diagnostic value in many types of tumors.
- Trial name
- FAPI-VTC (NCT05485792)
- Testing
- 18F-FAPI PET/CT and 18F-FDG PET/CT
- Volunteers
- 200 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
68Ga-FAPI PET/CT, Metastatic Adenoid Cystic Carcinoma
68Ga-FAPI PET/CT for the Detection of Adenoid Cystic Carcinoma(ACC)
This study was used to study the diagnostic value of 68Ga-FAPI, a novel fibroblast activating inhibitor, in metastatic adenoid cystic carcinoma（ACC）
- Trial name
- NCT05499936
- Testing
- 68Ga-FAPI
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Stage III Non-small-cell Lung Cancer
Omitting Clinical Target Volume of Unresectable Stage III Non-small-cell Lung Cancer.
About 20-30% of patients with stage III non-small cell lung cancer (NSCLC) are unresectable and definitive concurrent radiochemotherapy is the standard care.
- Trial name
- NCT05331833
- Testing
- The enrollment was randomly (1:1) assigned into the study group with CTV-omitted IMRT under PET-CT guidance and the control group with CTV-delineated IMRT using a random number table.
- Volunteers
- 90 people
- Sponsor
- Jianguo Sun
18F-FAPI, 18F-FDG
18F-FAPI PET Imaging in Pancreatic Adenocarcinoma
To explore the potential efficacy of 18F-FAPI-04 PET/CT for PDAC tumour staging and compare the results with those obtained using 18F-FDG PET/CT.
- Conditions
- 18F-FAPI, 18F-FDG, Pancreas Adenocarcinoma, Diagnosis
- Trial name
- NCT05884463
- Testing
- 18F-FAPI, 18F-FDG
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Zhejiang University
Metastatic Clear Cell Renal Cell Carcinoma
68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma
This is a prospective, single-center, single-arm, comparative phase 2 study in patients with metastatic clear cell renal cell carcinoma.
- Trial name
- NCT05879471
- Testing
- 68Ga-NY104 PET/CT
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Peking Union Medical College Hospital
High Grade Glioma
Contribution of Cerebral 18F-DOPA PET-CT Scan in High-grade Recurrent Gliomas
High-grade gliomas represent 60 to 70% of adult glial tumors and are highly aggressive with average survival from 12 to 15 months for glioblastomas (WHO grade IV gliomas) and from 2 to more than 5 years for WHO grade III gliomas.
- Trial name
- DORA (NCT04766632)
- Testing
- Brain PET-CT of 18F-DOPA
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Central Hospital, Nancy, France
Neoplasms
18F-FAPI-RGD PET/CT in Various Tumor Types
The clinical feasibility of 18F-FAPI-RGD PET/CT will be evaluated in 100 patients with various types of tumor, and the results will be compared with those of 18F-FDG.
- Trial name
- NCT06094530
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sichuan Provincial People's Hospital
Lung Cancer
Surveillance For New Lung Primaries
This clinical research protocol proposes to perform low dose helical computed tomographic (CT) scanning in 250 high-risk patients (125/year for two years) in order to detect lung carcinomas when they are small and subject to…
- Trial name
- NCT00205413
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer
Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr
This study will be assessing the ability of PSMA-PET CT to determine the absence of clinically significant prostate cancer in patients on active surveillance (AS) with low risk and favorable intermediate-risk prostate cancer.
- Trial name
- ESCAPE (NCT05948657)
- Testing
- PSMA-PET CT
- Where
- 4 sites in United States
- Volunteers
- 200 people
- Sponsor
- Weill Medical College of Cornell University
Microvascular Coronary Artery Disease, Coronary Artery Disease
The MASTER-PACT Study
The goal of this clinical trial is to compare non-invasive myocardial perfusion reserve (MRR) to invasively measured MRR in patients suspected for coronary artery disease (CAD).
- Trial name
- MASTER-PACT (NCT06069401)
- Volunteers
- 40 people
- Sponsor
- Amsterdam UMC, location VUmc
Renal Cell Carcinoma
89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
This is an exploratory clinical trial to assess the potential of 89Zr-DFO-Atezolizumab Positron Emission Tomography/Computed Tomography (PET/CT) scans in patients with locally advanced or metastatic renal cell carcinoma (RCC).
- Trial name
- NCT04006522
- Testing
- 89Zr-DFO-Atezolizumab, Positron Emission Tomography/Computed Tomography
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- James Brugarolas
Lung Neoplasms
Pulmonary Ventilation/Perfusion Imaging for the Prediction of Postoperative Residual Pulmonary Function
Lung cancer is one of the most common malignant tumors in the world and with the highest incidence in China. Surgery is the most effective therapeutic method for primary lung cancer.
- Trial name
- NCT03357094
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Beijing Tongren Hospital
Thyroid Cancer, RAI-Refractory Thyroid Cancer
I-124 PET/CT Imaging and Dosimetry for RAI-Naïve or Refractory Thyroid Cancer
The objective of this study is to demonstrate the clinical utility of I-124 PET/CT imaging and dosimetry in patients with thyroid cancer including 1) Evaluation of extent (volume and pattern) of remnant tissue in post total…
- Trial name
- NCT06443866
- Testing
- Disease status detection, Theranostic dosimetry, I-124 PET/CT imaging
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Miami Cancer Research Center, Inc.
Prostate Cancer
Monocentric Observational Study on the Diagnostic and Prognostic Role of 18F-PSMA PET (PET/CT and PET/MR) in Prostate Cancer
The general objective of this retrospective and prospective study is to evaluate the diagnostic and prognostic role of a quantitative analysis of PET images with 18F-PSMA in all stages of the disease in patients with prostate…
- Trial name
- NCT06167629
- Testing
- PET 18F-PSMA
- Where
- Italy
- Volunteers
- 2,500 people
- Sponsor
- IRCCS San Raffaele
Kidney Transplant Rejection, Kidney Transplant; Complications
Added Value of 18 FDG Pet-scanner in Diagnosis and Management of Subclinical Rejection in Kidney Transplant Patients
The renal biopsy (RB) represents the gold-standard for the diagnosis of acute renal transplant rejection (AR), and allows early verification of a so-called "subclinical" rejection, ie without any clinical or biological…
- Trial name
- NCT04702022
- Testing
- 18FDG PET / CT
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- University of Liege
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.